Nanoparticle delivery systems for cancer therapy: Advances in clinical and preclinical research

Clinical and Translational Oncology

Volumn 14, Issue 2, 2012, Pages 83-93

  Egusquiaguirre, Susana Patricia ^a,b   Igartua, Manuela ^a,b   Hernández, Rosa María ^a,b   Pedraz, José Luis ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Cancer therapy; Drug delivery; Drug targeting; Nanoparticles; Nanotechnology

Indexed keywords

AD 70; ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; BIND 014; CAMPTOTHECIN; CISPLATIN; CPX 1; CRLX 101; CT 2013; CT 2106; CYCLOPHOSPHAMIDE; CYTARABINE; CYTARABINE PLUS DAUNORUBICIN; DAUNORUBICIN; DELIMOTECAN; DOCETAXEL; DOXORUBICIN; EXATECAN; FIRTECAN; IRINOTECAN; LIPID; LIPOPLATIN; LIPOSOME; MACROGOL; MBP 426; MCC 465; METHOTREXATE; MITOMYCIN C; MTX HSA; NANOCARRIER; NANOPARTICLE; NAVELBINE; NC 6004; NK 105; NK 911; OXALIPLATIN; PACLICAL; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEGAMOTECAN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POLYMER; PROLINDAC; SMALL INTERFERING RNA; SP 1049C; THERMODOX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; XMT 1001;

ACIDITY; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; BIOACCUMULATION; BIOENGINEERING; BLOOD VESSEL PERMEABILITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONTROLLED RELEASE FORMULATION; DISEASE ACTIVITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; GLIOBLASTOMA; GLIOMA; HUMAN; HYDROPHOBICITY; KAPOSI SARCOMA; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LYMPHATIC DRAINAGE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MICELLE; MULTIPLE MYELOMA; NANOBIOTECHNOLOGY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; REVIEW; SOLID TUMOR; STOMACH CANCER; TARGET CELL DESTRUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; POLYMERS;

EID: 84860471928     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0766-6     Document Type: Review

References (99)

1. World Health Organization (2011) Cancer. Fact Sheet #297
2. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823-837
3. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
4. Park JH, von Maltzahn G, Xu MJ et al (2010) Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci U S A 107:981-986
5. Sahoo SK, Parveen S, Panda JJ (2007) The present and future of nanotechnology in human health care. Nanomedicine 3:20-31 (Pubitemid 46428187)
6. Sahoo SK, Labhasetwar V (2003) Nanotech approaches to drug delivery and imaging. Drug Discov Today 8:1112-1120 (Pubitemid 37547917)
7. Shaffer C (2005) Nanomedicine transforms drug delivery. Drug Discov Today 10:1581-1582 (Pubitemid 41817601)
8. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. FASEB J 19:311-330 (Pubitemid 40316520)
9. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771-782
10. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818-1822 (Pubitemid 38374867)
11. Bae KH, Chung HJ, Park TG (2011) Nanomaterials for cancer therapy and imaging. Mol Cells 31:295-302
12. Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329-347 (Pubitemid 36297053)
13. Kohandel M, Kardar M, Milosevic M, Sivaloganathan S (2007) Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies. Phys Med Biol 52:3665-3677 (Pubitemid 46908587)
14. Maeda H, Wu J, Sawa T et al (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271-284 (Pubitemid 30122932)
15. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653-664
16. Padera TP, Kadambi A, di Tomaso E et al (2002) Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296:1883-1886 (Pubitemid 34596277)
17. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189-207
18. Cho K, Wang X, Nie S et al (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310-1316 (Pubitemid 351413909)
19. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25:4633-4646 (Pubitemid 44187614)
20. Liechty WB, Caldorera-Moore M, Phillips MA et al (2011) Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics. J Control Release 155:119-127
21. Bae YH, Park K (2011) Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 153:198-205
22. Torchilin VP (2010) Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol (197):3-53
23. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615-1626
24. Parveen S, Misra R, Sahoo SK (2011) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine (in press)
25. Lammers T, Kiessling F, Hennink WE, Storm G (2011) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release (in press)
26. Tagami T, Ernsting MJ, Li SD (2011) Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J Control Release 154:290-297
27. Tagami T, Ernsting MJ, Li SD (2011) Effi cient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J Control Release 152:303-309
28. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505-515
29. Kazuo M (2011) Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 63:161-169
30. Owens DE 3rd, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93-102 (Pubitemid 41773257)
31. Gratton SE, Ropp PA, Pohlhaus PD et al (2008) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 105: 11613-11618
32. Bangham AD, Horne RW (1964) Negative staining of phospholipids and their structural modifi cation by surface-active agents as observed in the electron microscope. J Mol Biol 8:660-668
33. Sapra P, Allen TM (2003) Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42:439-462 (Pubitemid 36700404)
34. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A (2005) Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16:691-707 (Pubitemid 41104918)
35. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905 (Pubitemid 28446849)
36. Gaitanis A, Staal S (2010) Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol 624:385-392
37. Keller AM, Mennel RG, Georgoulias VA et al (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxanerefractory advanced breast cancer. J Clin Oncol 22:3893-3901 (Pubitemid 41079870)
38. O'Brien MER, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable effi cacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for fi rst-line treatment of metastatic breast cancer. Ann Oncol 15:440-449 (Pubitemid 38444547)
39. Northfelt DW, Dezube BJ, Thommes JA et al (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16:2445-2451 (Pubitemid 28309039)
40. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322 (Pubitemid 32642183)
41. Sparano JA, Makhson AN, Semiglazov VF et al (2009) Pegylated liposomal doxorubicin plus docetaxel signifi cantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with ad vanced breast cancer previously treated with neoadjuvant- adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 27:4522-4529
42. Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25:3892-3901 (Pubitemid 47477266)
43. Davies Cde L, Lundstrom LM, Frengen J et al (2004) Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res 64:547-553 (Pubitemid 38124453)
44. Harris L, Batist G, Belt R et al; TLC D-99 Study Group (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as fi rst-line therapy of metastatic breast carcinoma. Cancer 94:25-36 (Pubitemid 34049039)
45. Batist G, Ramakrishnan G, Rao CS et al (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454 (Pubitemid 32202552)
46. Gill PS, Wernz J, Scadden DT et al (1996) Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14:2353-2364 (Pubitemid 26264888)
47. www.clinicaltrials.gov
48. Stathopoulos GP, Boulikas T (2012) Lipoplatin formulation review article. J Drug Deliv 581363-581372
49. Zamboni WC, Ramalingam S, Friedland DM et al (2009) Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 15:1466-1472
50. Batist G, Gelmon KA, Chi KN et al (2009) Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 15:692-700
51. Sankhala KK (2009) A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J Clin Oncol 27:2535
52. Matsumura Y, Gotoh M, Muro K et al (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15:517-525 (Pubitemid 38444560)
53. Wang X, Wang Y, Chen ZG, Shin DM (2009) Advances of cancer therapy by nanotechnology. Cancer Res Treat 41:1-11
54. Miele E, Spinelli GP, Miele E et al (2009) Albumin- bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed 4:99-105
55. Crown J, O'Leary M (2000) The taxanes: an update. Lancet 355:1176-1178 (Pubitemid 30172946)
56. Rowinsky EK, Eisenhauer EA, Chaudhry V et al (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15 (Pubitemid 23239390)
57. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albuminbound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803 (Pubitemid 46657376)
58. Roy V, LaPlant BR, Gross GG et al; North Central Cancer Treatment Group (2009) Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 20:449-453
59. Lobo C, Lopes G, Baez O et al (2010) Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as fi rst-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 123:427-435
60. Svenson S, Wolfgang M, Hwang J et al (2011) Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release 153:49-55
61. Davis ME (2009) The fi rst targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659-668
62. Ozpolat B, Sood AK, Lopez-Berestein G (2010) Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 267:44-53
63. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129-138
64. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA (2008) Emerging nanopharmaceuticals. Nanomedicine 4:273-282
65. Kim DW, Kim SY, Kim HK et al (2007) Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 18:2009-2014
66. Lee KS, Chung HC, Im SA et al (2008) Multicenter phase II trial of Genexol-PM, a Cremophorfree, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108:241-250 (Pubitemid 351311357)
67. Kim HJ, Kim KH, Yun J et al (2011) Phase II clinical trial of Genexol(R) (paclitaxel) and carboplatin for patients with advanced non-small cell lung cancer. Cancer Res Treat 43:19-23
68. Matsumura Y, Hamaguchi T, Ura T et al (2004) Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775-1781 (Pubitemid 39664964)
69. Kato K, Chin K, Yoshikawa T et al (2011) Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs (in press)
70. Plummer R, Wilson RH, Calvert H et al (2011) A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer 104:593-598
71. Hamaguchi T, Doi T, Eguchi-Nakajima T et al (2010) Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 16:5058-5066
72. Valle JW, Armstrong A, Newman C et al (2011) A phase 2 study of SP1049C, doxorubicin in P-glycoprotein- targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs 29:1029-1037
73. Vasey PA, Kaye SB, Morrison R et al (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: fi rst member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 5:83-94 (Pubitemid 29045181)
74. Rademaker-Lakhai JM, Terret C, Howell SB et al (2004) A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 10:3386-3395 (Pubitemid 38685444)
75. Nowotnik DP, Cvitkovic E (2009) ProLindac™ (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv Drug Deliv Rev 61:1214-1219
76. Sabbatini P, Aghajanian C, Dizon D et al (2004) Phase II study of CT-2103 in patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 22:4523-4531 (Pubitemid 41185119)
77. Homsi J, Simon GR, Garrett CR et al (2007) Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 13:5855-5861 (Pubitemid 47583911)
78. Bigioni M, Parlani M, Bressan A et al (2009) Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants. Int J Cancer 125:2456-2464
79. Veltkamp SA, Witteveen EO, Capriati A et al (2008) Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clin Cancer Res 14:7535-7544
80. Danhauser-Riedl S, Hausmann E, Schick HD et al (1993) Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOXOXD). Invest New Drugs 11:187-195 (Pubitemid 23277239)
81. Bolling C, Graefe T, Lübbing C et al (2006) Phase II study of MTX-HSA in combination with Cisplatin as fi rst line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest New Drugs 24:521-527 (Pubitemid 44273028)
82. Aleku M, Schulz P, Keil O et al (2008) Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68:9788-9798
83. Chawla SP, Chua VS, Fernandez L et al (2010) Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine- resistant metastatic pancreatic cancer. Mol Ther 18:435-441
84. Prakash S, Malhotra M, Shao W et al (2011) Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Adv Drug Deliv Rev 63:1340-1351
85. Cheng Y, Zhao L, Li Y, Xu T (2011) Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem Soc Rev 40:2673-2703
86. Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, Blanco-Prieto MJ (2009) Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol 5:323-343
87. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC (2011) Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A 108:1850-1855
88. Battaglia L, Serpe L, Muntoni E et al (2011) Methotrexate-loaded SLNs prepared by coacervation technique: in vitro cytotoxicity and in vivo pharmacokinetics and biodistribution. Nanomedicine (Lond) 6:1561-1573
89. Ding D, Zhu Z, Liu Q et al (2011) Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor effi ciency in vivo and penetration in tumors. Eur J Pharm Biopharm 79:142-149
90. Parhi P, Mohanty C, Sahoo SK (2011) Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy. Acta Biomater 7:3656-3669
91. Jain A, Jain SK, Ganesh N et al (2010) Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine 6:179-190
92. Lammers T, Peschke P, Kühnlein R et al (2007) Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J Control Release 117:333-341 (Pubitemid 46216581)
93. Lammers T, Subr V, Ulbrich K et al (2010) Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today 5:197-212
94. Yang X, Dou S, Sun T et al (2011) Systemic delivery of siRNA with cationic lipid assisted PEGPLA nanoparticles for cancer therapy. J Control Release 156:203-211
95. Duan J, Zhang Y, Han S et al (2010) Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin- loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 400:211-220
96. Oh KS, Song JY, Cho SH et al (2010) Paclitaxel- loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy. J Control Release 148:344-350
97. Zhu Z, Li Y, Li X et al (2010) Paclitaxel-loaded poly(N-vinylpyrrolidone) -b-poly(?-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release 142:438-446
98. Kim J, Kim Y, Park K et al (2008) Antitumor effi cacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release 127:41-49
99. Zhang W, Shi Y, Chen Y et al (2010) Enhanced antitumor effi cacy by Paclitaxel-loaded Pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 75:341-353